Evidence map›Paper›PMID 41779364›Full record

ArticleOphthalmology and therapy2026

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Alice M Kitay, Anne Tillmann, Isabel Pfister, Christin Schild, Matteo Bonanata, Katharina Heck, Tahm Spitznagel, Felix Gabathuler, Nicolo Bartolomeo, Simon Magnin and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Alice M Kitay *Talacker Augen Zentrum Zürich (TAZZ), Zurich, Switzerland.
Anne Tillmann *Augenarzt Praxisgemeinschaft Gutblick AG, Pfäffikon, Switzerland.
Isabel PfisterBerner Augenklinik and Swiss Eye Institute, Bern, Switzerland.
Christin SchildBerner Augenklinik and Swiss Eye Institute, Bern, Switzerland.
Matteo BonanataDepartment of Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland (INSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
Katharina HeckVista Augenklinik Binningen, Binningen, Switzerland.
Tahm SpitznagelDepartment of Ophthalmology, Stadtspital Zurich, Zurich, Switzerland.
Felix GabathulerDepartment of Ophthalmology, University Hospital Zurich, Zurich, Switzerland.
Nicolo BartolomeoSwiss Visio Montchoisi, Lausanne, Switzerland.
Simon MagninHôpital Ophtalmique Jules Gonin, Lausanne, Switzerland.
Jordan LöligerUniversity Hospital Basel, Basel, Switzerland.
Marion R MunkAugenarzt Praxisgemeinschaft Gutblick AG, Pfäffikon, Switzerland.
Moreno MenghiniDepartment of Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland (INSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
Katja HatzVista Augenklinik Binningen, Binningen, Switzerland.
Gábor Márk SomfaiDepartment of Ophthalmology, Stadtspital Zurich, Zurich, Switzerland.
Sandrine ZweifelDepartment of Ophthalmology, University Hospital Zurich, Zurich, Switzerland.
Aude AmbresinSwiss Visio Montchoisi, Lausanne, Switzerland.
Chiara M EandiHôpital Ophtalmique Jules Gonin, Lausanne, Switzerland.
Nicolas FeltgenUniversity Hospital Basel, Basel, Switzerland.
Andreas WeinbergerPallas-Klinik Olten, Olten, Switzerland.
Justus G Garweg *Berner Augenklinik and Swiss Eye Institute, Bern, Switzerland. justus.garweg@augenklinik-bern.ch.ORCID http://orcid.org/0000-0003-3973-5082
Malaika M Kurz-Levin *Talacker Augen Zentrum Zürich (TAZZ), Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis multicenter, longitudinal, observational real-world study evaluated the efficacy and safety of switching to intravitreal aflibercept 8 mg (Afl 8) in pretreated eyes with neovascular age-related macular degeneration (nAMD) within the Swiss Retina Research Network. A total of 283 eyes from 245 patients previously treated with other anti-vascular endothelial growth factor (anti-VEGF) agents (aflibercept 2 mg, faricimab, and ranibizumab) were included, with 1-year efficacy outcomes analyzed in 246 eyes and safety assessed in all treated eyes.

methodsWe recorded demographics, baseline functional and anatomical parameters-including spectacle-corrected visual acuity (VA) and optical coherence tomography (OCT) data-treatment history and outcomes over 12 months after switching to Afl 8. The main outcome measures were change in VA, central subfield thickness (CST), presence of intra- and subretinal fluid (IRF/SRF) and pigment epithelial detachment (PED), treatment intervals, and adverse events.

resultsTwelve months after the switch to Afl 8, mean VA remained stable, while mean CST decreased from 329.1 to 302.8 µm (p < 0.001). The portion of eyes without retinal fluid increased from 29.9% at baseline to 47.5% after 12 months. In parallel, the mean treatment interval was extended by 32.3% from 7.1 to 9.4 weeks (p < 0.001). At 1 year, 35.4% of eyes reached intervals of 8-11 weeks, while 20.2% achieved intervals of 12 weeks or longer. Intraocular inflammation was reported in 11 cases (3.9%).

conclusionsIn pretreated nAMD eyes with high treatment demand, switching to Afl 8 resulted in a significant anatomical improvement and longer treatment intervals in a majority of patients. These real-world results highlight the therapeutic potential of Afl 8, with no new or unexpected safety issues.

Indexed as

AfliberceptAge-related macular degenerationAnti-VEGFReal-worldRetinaSwiss Retina Research NetworkSwitcher

Identifiers

PMID41779364
PMCPMC13046877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.